ワクチンの世界市場：サブユニットワクチン、弱毒生ワクチン、結合型ワクチン、不活化ワクチン、 組換え型ワクチン、トキソイドワクチン等...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 23
1.5 LIMITATIONS 23
1.6 STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24
2.1 MARKET SIZE ESTIMATION 25
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.3 MARKET SHARE ESTIMATION 28
2.4 KEY DATA FROM SECONDARY SOURCES 29
2.5 KEY DATA FROM PRIMARY SOURCES 29
2.6 KEY INDUSTRY INSIGHTS 30
2.7 ASSUMPTIONS 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 35
4.1 VACCINES MARKET HAS HIGH GROWTH POTENTIAL 35
4.2 VACCINES MARKET, BY TYPE 36
4.3 VACCINES MARKET, BY REGION 37
4.4 VACCINES MARKET, BY DISEASE INDICATION 38
4.5 VACCINES MARKET, BY END USER 39
4.6 LIFECYCLE ANALYSIS, BY REGION 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 42
5.2 MARKET SEGMENTATION 42
5.2.1 VACCINES MARKET, BY TECHNOLOGY 42
5.2.2 VACCINES MARKET, BY TYPE 42
5.2.3 VACCINES MARKET, BY DISEASE INDICATION 43
5.2.4 VACCINES MARKET, BY END USER 43
5.2.5 VACCINES MARKET, BY REGION 44
 
5.3 MARKET DYNAMICS 45
5.3.1 DRIVERS 45
5.3.1.1 High prevalence of diseases 45
5.3.1.2 Rising government and nongovernment funding for vaccine development 46
5.3.1.3 Increasing investments by companies 46
5.3.1.4 Technological advancements 47
5.3.2 RESTRAINTS 48
5.3.2.1 Huge capital investments 48
5.3.2.2 Stringent regulatory procedures 48
5.3.3 OPPORTUNITIES 49
5.3.3.1 High growth prospects in emerging markets 49
5.3.3.2 Therapeutic vaccines 49
5.3.3.3 Adjuvant vaccines 50
5.3.4 CHALLENGES 51
5.3.4.1 Inadequate access to vaccines 51
5.3.4.2 Vaccine pricing 51
5.3.5 BURNING ISSUES 52
5.3.5.1 Failure of vaccines 52

6 INDUSTRY INSIGHTS 53
6.1 PORTER’S FIVE FORCES ANALYSIS 53
6.1.1 THREAT FROM NEW ENTRANTS 53
6.1.2 BARGAINING POWER OF SUPPLIERS 54
6.1.3 BARGAINING POWER OF BUYERS 54
6.1.4 INTENSITY OF COMPETITIVE RIVALRY 54
6.1.5 THREAT OF SUBSTITUTES 54
6.2 VALUE CHAIN ANALYSIS 54
6.3 SUPPLY CHAIN ANALYSIS 55
6.4 TECHNOLOGY TRENDS FOR ADJUVANTS 57
6.4.1 DRIVERS 57
6.4.1.1 Increasing Use of Adjuvants in Vaccine-preventable Diseases 57
6.4.1.2 Rising Government Investments 57
6.4.2 RESTRAINS 57
6.4.2.1 High Cost of Research 57
6.4.2.2 Regulatory Hurdles 58
6.4.3 OPPORTUNITIES 58
6.4.3.1 Combined Adjuvants 58
6.4.3.2 Vaccines for Young Children 58
6.4.3.3 Pandemic Diseases 58
6.4.4 CHALLENGES 58
6.4.4.1 Identification of Adjuvants 58
6.4.4.2 Technological Limitations 58
6.4.5 TRENDS 59
6.4.5.1 Collaborations 59
6.4.5.2 New Adjuvant Technologies 59
6.5 INVESTMENT ANALYSIS 61
6.6 REGULATORY LANDSCAPE 64
6.6.1 NORTH AMERICA 64
6.6.2 EUROPE 65
6.6.3 ASIA 65
6.6.4 ROW 66
6.7 PATENT ANALYSIS 66
6.8 KEY PIPELINE PRODUCTS 68
6.9 STRATEGIC BENCHMARKING 70

7 VACCINES MARKET, BY TECHNOLOGY 72
7.1 INTRODUCTION 73
7.2 SUBUNIT VACCINES 74
7.3 LIVE ATTENUATED VACCINES 77
7.4 CONJUGATE VACCINES 79
7.5 INACTIVATED VACCINES 81
7.6 RECOMBINANT VECTOR VACCINES 84
7.7 TOXOID VACCINES 87
7.8 SYNTHETIC VACCINES 89
7.9 DENDRITIC CELL VACCINES 93

8 VACCINES MARKET, BY TYPE 95
8.1 INTRODUCTION 96
8.2 PREVENTIVE VACCINES 97
8.3 THERAPEUTIC VACCINES 100

9 VACCINES MARKET, BY DISEASE INDICATION 103
9.1 INTRODUCTION 104
9.2 INFECTIOUS DISEASES 105
9.2.1 PNEUMOCOCCAL 108
9.2.2 INFLUENZA 109
9.2.3 DTP 109
9.2.4 HEPATITIS 109
9.2.5 ROTAVIRUS 110
9.2.6 VARICELLA 110
9.2.7 MENINGOCOCCAL 110
9.2.8 POLIO 111
9.2.9 MMR 111
9.2.10 OTHERS 112
9.3 CANCER 112
9.3.1 CERVICAL CANCER 115
9.3.2 OTHER CANCERS 115
9.4 ALLERGIES 116

10 VACCINES MARKET, BY END USER 119
10.1 INTRODUCTION 120
10.2 PEDIATRICS 121
10.3 ADULTS 124

11 GLOBAL VACCINES MARKET, BY REGION 127
11.1 INTRODUCTION 128
11.2 NORTH AMERICA 131
11.2.1 U.S. 133
11.2.2 CANADA 136
11.3 EUROPE 138
11.3.1 GERMANY 141
11.3.2 FRANCE 145
11.3.3 U.K. 147
11.3.4 ITALY 149
11.3.5 SPAIN 151
11.3.6 REST OF EUROPE (ROE) 153
11.4 ASIA 155
11.4.1 JAPAN 158
11.4.2 CHINA 160
11.4.3 INDIA 163
11.4.4 REST OF ASIA (ROA) 165
11.5 REST OF THE WORLD (ROW) 167

12 COMPETITIVE LANDSCAPE 171
12.1 OVERVIEW 171
12.2 MARKET SHARE ANALYSIS 171
12.3 COMPETITIVE SITUATION AND TRENDS 173
12.3.1 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS 174
12.3.2 REGULATORY APPROVALS 174
12.3.3 ACQUISITIONS 175
12.3.4 OTHER DEVELOPMENTS 176

13 COMPANY PROFILES 177
13.1 INTRODUCTION 177
13.2 GLAXOSMITHKLINE, PLC. 178
13.3 MERCK & CO., INC. 181
13.4 SANOFI PASTEUR 184
13.5 PFIZER, INC. 187
13.6 NOVARTIS AG 189
13.7 BAVARIAN NORDIC 192
13.8 CSL LIMITED 194
13.9 EMERGENT BIOSOLUTIONS, INC. 196
13.10 JOHNSON & JOHNSON 198
13.11 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA) 200
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

14 APPENDIX 202
14.1 RECENT DEVELOPMENTS 202
14.1.1 GLAXOSMITHKLINE, PLC. 202
14.1.2 SANOFI PASTEUR 203
14.1.3 NOVARTIS AG 204
14.1.4 EMERGENT BIOSOLUTIONS INC. 204
14.2 INSIGHTS FROM INDUSTRY EXPERTS 205
14.3 DISCUSSION GUIDE 206
14.4 AVAILABLE CUSTOMIZATIONS 208
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 209
14.6 RELATED REPORTS 210